Fig. 7: Sphingosine-1-phosphate receptor 1 (S1PR1) signaling could be inhibited by VPC 23019, sphingosine-1-phosphate receptor 1 antagonist, in vitro.
From: S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer
a, b RhoA and vascular endothelial growth factor (VEGF) measurement in the different treatment groups by G-LISA and ELISA. c, d MCF-7-shS1PR1, MCF-7-IN, and 231-S1PR1-IN groups promoted vasculogenic mimicry (VM) channel formation (100 × , bar 50 µm) and reduced the number of endothelium-dependent vessels (EDVs) in 3D culture (40 × , bar 100 µm). e The protein levels of S1PR1, VE-cadherin, VE-cadherin (Y731), β-catenin were changed in MCF-7-shS1PR1, MCF-7-IN, and 231-S1PR1-IN groups. f The change of S1PR1, VE-cadherin and β-catenin was shown by immunofluorescence staining (100 × , bar 50 µm). Shown are mean ± SD, *p < 0.05
